NDAORALTABLET
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
TINDAMAX (tinidazole) by Mission Therapeutics. Approved for bacterial vaginosis. First approved in 2004.
Drug data last refreshed 19h ago
Mechanism of Action
Pharmacologic Class:
Nitroimidazole Antimicrobial
Indications (1)
Clinical Trials (5)
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
Started Jul 2025
40 enrolled
Mycoplasma GenitaliumNon-gonococcal Urethritis (NGU)
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
Started Oct 2007
37 enrolled
Bacterial Vaginosis
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
Started Nov 2006
305 enrolled
Urethritis
Treatment of Bacterial Vaginosis With Oral Tinidazole
Started Jan 2005
200 enrolled
Bacterial Vaginosis
Treatment of Bacterial Vaginosis (BV) With Tinidazole
Started Nov 2004
593 enrolled
Bacterial Vaginosis
Worked on TINDAMAX at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.